IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer - Yahoo Finance

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  Yahoo Finance

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer.



Comments

Popular posts from this blog

“Stem cells: A possible treatment for severe respiratory failure, a COVID-19 complication - Mirage News” plus 1 more

“Screening for hearing loss in primary care - Contemporary Pediatrics” plus 1 more

“Evidence of cross-species filovirus transmission from bats to humans - EurekAlert” plus 2 more